Abstract
Chemotherapy is the only available option for treatment of metastatic cancers. However, increasing evidences of drug resistance and non‐specific toxicity of these agents limits their therapeutic outcomes. Nanoparticle mediated targeted therapies is one of the attractive therapeutic option to overcome these problems. We have formulated curcumin encapsulating poly(lactic‐co‐glycolic acid) (PLGA) nanoparticles (NPs) coated with annexin A2 antibody to target prostate cancer as a model for this project. We characterized these NPs for particle size, stability, efficiency of antibody attachment, surface charge etc. We performed cellular uptake studies in prostate cancer cells and quantified the amount of drug taken up by the cells. Our results showed that the average size of these NPs is 151nm and 179nm before and after attachment of antibody respectively. The cytometric analysis showed that approximately 87.5% of NPs were coated with annexin A2 antibody. The antibody coated NPs have nearly neutral surface charge and are readily taken up by the cell. When injected intravenously in athymic mice bearing xenografts of DU‐145 prostate cancer cells (annexin A2 positive), the annexin A2 antibody coated NPs preferentially localize to the tumor compared to uncoated NPs. In summary, we have formulated a novel targeted drug delivery system which will be a potent tool for therapeutic intervention of metastatic cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
